Have a personal or library account? Click to login
Interactive role of breast cancer on dyslipidemia and hypertension metabolic risk according to treatment exposure and menopausal status Cover

Interactive role of breast cancer on dyslipidemia and hypertension metabolic risk according to treatment exposure and menopausal status

Open Access
|May 2021

Figures & Tables

Prevalence of dyslipidemia risk factors and hypertension in pre and postmenopause according to treatment exposure(1, 2, 3, 4, 5)

Metabolic riskNewly-diagnosed (N = 134)Recently-diagnosed (N = 262)Whole sample (N = 396)

Premeno-pause (N = 80)Postmeno-pause (N = 54)Premeno-pause (N = 149)Postmeno-pause (N = 113)Premeno-pause (N = 229)Postmeno-pause (N = 167)

n%n%n%n%n%n%
SBP* (mmHg)64.586.0135.02911.1194.8379.3
DBP* (mmHg)86.01611.9207.62911.1287.14511.4
HDL* (mg/dl)4835.83425.410439.77829.915238.411228.3
TG* (mg/dl)5641.84634.311644.310038.317243.414636.9

Prevalence of the dyslipidemia risk factors and hypertension according to treatment exposure(1, 2, 3, 4)

VariablesCut-off pointsNewly diagnosed (n = 134)Recently – diagnosed (n = 262)Whole sample (n = 396)

Non-chemo (n = 86)Chemo (n = 176)Total (n = 262)

n%n%n%n%n%
SBP (mmHg)> 1301410.4a89.3a3419.3b4216.0b5614.1
DBP (mmHg)> 852417.9a1112.8a3821.6a4918.7a7318.4
Overt hypertension*3123.11011.64927.85922.59022.7
HDL-C (mg/dl)< 508261.2a7081.4b11263.6a18269.5b26466.7
TG (mg/dl)> 15010276.1a7384.9b14381.2b21682.4b31880.3
TC (mg/dl)> 2009067.2a7587.2b13777.8b21280.9b30276.3
Overt dyslipidemia*75.222.3105.7124.6194.8

Dyslipidemia and hypertension characteristic in pre and postmenopause women according to treatment exposure(1, 2, 3, 4, 5)

Metabolic risksNewly-diagnosed (N = 134)Recently-diagnosed (N = 262)Whole sample (N = 396)

Premeno-pause (N = 80)Postmeno-pause (N = 54)Premeno-pause (N = 149)Postmeno-pause (N = 113)Premeno-pause (N = 229)Postmeno-pause (N = 167)

Mean ± SEMMean ± SEMMean ± SEMMean ± SEMMean ± SEMMean ± SEM
SBP*(mmHg)117.11.5121.11.7a118.50.9136.21.2b118.00.8129.31.0
DBP(mmHg)76.61.480.91.178.30.680.21.078.00.680.00.7
HDL-C(mg/dl)47.90.947.71.644.80.846.70.946.00.647.00.8
TG* (mg/dl)182.56.9215.39.6201.76.1223.57.4195.04.7221.05.9

Dyslipidaemia and hypertension characteristics according to treatment exposure(1, 2, 3)

CharacterNewly-diagnosed (n = 134)Recently – diagnosed (n=262)Whole sample (n = 396)

Non-chemo (n = 86)Chemo (n = 176)Total (n = 262)

Mean ± SEMMean ± SEMMean ± SEMMean ± SEMMean ± SEM
SBP (mmHg)119.11.1a119.51.2a123.00.9b121.90.8a120.90.6
DBP (mmHg)78.41.0a78.00.8a79.60.7a79.10.5a78.80.5
HDL-C(mg/dl)47.80.8a42.91.0b47.60.7a45.60.6b46.40.5
LDL-C (mg/dl)126.99.0a141.03.4a128.82.8a132.82.2a130.83.4
TG (mg/dl)195.75.8a221.88.9b205.95.6b211.14.7b205.93.7

Age-controlled partial correlation coefficients of dyslipidemia risk factors and hypertension with obesity indices and selected biomarkers in the study sample(1–2)

Metabolic risksBMIWCWHpRWHtRleptinHOMAC-peptide
SBR(mmHg)0.040.080.120.080.100.14**0.03
DBR (mmHg)0.010.17***0.15**0.13*0.080.10*−0.02
HDL-C(mg/dl)−0.11*−0.11*−0.09−0.13**−0.020.020.03
TG (mg/dl)0.050.16***0.080.15**−0.11*0.030.02
DOI: https://doi.org/10.2478/fco-2019-0018 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Language: English
Page range: 39 - 46
Submitted on: Jun 30, 2018
Accepted on: Apr 29, 2019
Published on: May 2, 2021
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year

© 2021 Safaa A. Al-Zeidaneen, Mousa N. Ahmad, Ali D. Al-Ebous, Rawan MohD Al Saudi, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.